Vascular endothelial growth factor receptor 2 and downstream p38 mitogen-activated protein kinase are possible candidate markers of intrinsic resistance to adjuvant endocrine treatment in steroid receptor positive breast cancer

Breast Cancer Research and Treatment

Volumn 125, Issue 2, 2011, Pages 457-465

  Linderholm, Barbro K ^a   Hellborg, Henrik ^a   Johansson, Ulla ^a   Skoog, Lambert ^a   Lehtiö, Janne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Intrinsic and required resistance; p38MAPK; Tamoxifen; VEGFR2

Indexed keywords

ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TISSUE LEVEL; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; SURVIVAL RATE; TAMOXIFEN; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 78650988964     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1252-x     Document Type: Article

References (34)

1. D Hanahan R Weinberg 2000 The hallmarks of cancer Cell 100 57 70 1:CAS:528:DC%2BD3cXks1CktA%3D%3D 10.1016/S0092-8674(00)81683-9 10647931
2. P Guo Q Fang HQ Tao CA Schafer BM Fenton I Ding B Hu SY Cheng 2003 Overexpression of vascular endothelial growth factor by MCF-7 breast cancer cells promotes estrogen-independent tumor growth in vivo Cancer Res 63 4684 4691 1:CAS:528:DC%2BD3sXmtFersbg%3D 12907650
3. J Kroll J Waltenberger 1999 A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells Biochem Biophys Res Commun 265 636 639 1:CAS:528:DyaK1MXnvFaqtLk%3D 10.1006/bbrc.1999.1729 10600473
4. R Aesoy BC Sanchez JH Norum R Lewensohn K Viktorsson B Linderholm 2008 An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells Mol Cancer Res 10 1630 1638 10.1158/1541-7786.MCR-07-2172
5. J Folkman 2003 Fundamental concepts of the angiogenic process Curr Mol Med 3 643 651 1:CAS:528:DC%2BD3sXotFOjsrg%3D 10.2174/1566524033479465 14601638 Review (Pubitemid 37236406)
6. TP Garrington GL Johnson 1999 Organization and regulation of mitogen-activated protein kinase signaling pathways Curr Opin Cell Biol 11 211 218 1:CAS:528:DyaK1MXisFWlsb8%3D 10.1016/S0955-0674(99)80028-3 10209154 Review (Pubitemid 29164036)
7. GR Fanger 1999 Regulation of the MAPK family members: role of subcellular localization and architectural organization Histol Histopathol 14 887 894 1:CAS:528:DyaK1MXltFOisbc%3D 10425559 Review
8. JM Kyriakis J Avruch 2001 Mammalian Mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation Physiol Rev 81 807 869 1:CAS:528:DC%2BD3MXislCrsb8%3D 11274345
9. LE Rutqvist B Cedermark T Fornander U Glas H Johansson B Nordenskjöld S Rotstein L Skoog A Somell T Theve, et al. 1989 The relationship between hormone receptor content and the effect of adjuvant tamoxifen in operable breast cancer J Clin Oncol 7 10 1474 1484 1:STN:280:DyaL1MzotFOksQ%3D%3D 2674335
10. EM Cornier MF Wolf VC Jordan 1989 Decrease in estradiol-stimulated progesterone receptor production in MCF-7 cells by epidermal growth factor and possible clinical implication for paracrine-regulated breast cancer growth Cancer Res 49 576 580
11. X Cui P Zhang W Deng S Oesterreich Y Lu GB Mills AV Lee 2003 Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer Mol Endocrinol 17 575 588 1:CAS:528: DC%2BD3sXivFClu7o%3D 10.1210/me.2002-0318 12554765 (Pubitemid 36403572)
12. C Osipo C Gajdos D Cheng VC Jordan 2005 Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy J Steroid Biochem Mol Biol 93 249 256 1:CAS:528:DC%2BD2MXjs1Cru70%3D 10.1016/j.jsbmb.2004.12.005 15860267 (Pubitemid 40602497)
13. CK Osborne J Pippen SE Jones LM Parker M Ellis S Come SZ Gertler JT May G Burton I Dimery A Webster C Morris R Elledge A Buzdar 2002 Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 3386 3395 1:CAS:528:DC%2BD38XntVyjsbo%3D 10.1200/JCO.2002.10.058 12177098
14. A Howell JF Robertson J Quaresma Albano A Aschermannova L Mauriac UR Kleeberg I Vergote B Erikstein A Webster C Morris 2002 Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 3396 3403 1:CAS:528:DC%2BD38XntVyjsbs%3D 10.1200/JCO.2002.10.057 12177099
15. B Linderholm J Bergqvist H Hellborg U Johansson M Linderholm E von Schoultz G Elmberger L Skoog J Bergh 2009 Shorter survival times following adjuvant endocrine therapy in oestrogen (ER)-and progesterone receptor (PgR) positive breast cancer (BC) overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor (VEGF) Med Oncol 26 480 490 1:CAS:528:DC%2BD1MXhsVKhurrL 10.1007/s12032-008-9157-9 19130322
16. BK Linderholm H Hellborg U Johansson E Elmberger L Skoog J Lehtiö R Lewensohn 2009 Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple negative breast cancer Ann Oncol 20 1639 1646 1:STN:280:DC%2BD1MnjvFyitQ%3D%3D 10.1093/annonc/mdp062 19549711
17. J Geurts-Moespot R Leake TJ Benraad CG Sweep 2000 Twenty years of experience with the steroid receptor external quality assessment program-the paradigm for tumour biomarker EQA studies. On behalf of the EORTC Receptor and Biomarker Study Group Int J Oncol 17 13 22 1:CAS:528:DC%2BD3cXksV2rurw%3D 10853012 Review
18. B Linderholm B Tavelin K Grankvist R Henriksson 1998 Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma J Clin Oncol 16 3121 3131 1:CAS:528:DyaK1cXmtFSlsb4%3D 9738584
19. B Linderholm K Grankvist N Wilking M Johansson B Tavelin R Henriksson 2000 Correlation of Vascular Endothelial Growth Factor (VEGF) and survival, metastasis sites and responsiveness to adjuvant systemic treatment in primary node-positive breast carcinoma J Clin Oncol 18 1423 1431 1:CAS:528: DC%2BD3cXivVeisro%3D 10735889
20. JA Foekens HA Peters N Grebenchtchikov MP Look ME Meijer-van Gelder A Geurts-Moespot, et al. 2001 High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer Cancer Res 61 5407 5414 1:CAS:528:DC%2BD3MXnsVCru7o%3D 11454684
21. P Manders LV Beex VC Tjan-Heijnen PN Span CG Sweep 2003 Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma Cancer 98 2125 2132 1:CAS:528:DC%2BD3sXps1arsrc%3D 10.1002/cncr.11764 14601081 (Pubitemid 37392415)
22. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics 2005 Reporting recommendations for tumor marker prognostic studies J Clin Oncol 23 9067 9072 10.1200/JCO.2004.01.0454 16172462
23. RT Poon ST Fan J Wong 2001 Clinical implications of circulating angiogenic factors in cancer patients J Clin Oncol 19 1207 1225 1:CAS:528:DC%2BD3MXhvFertrc%3D 11181687
24. L Rydén K Jirström PO Bendahl M Fernö B Nordenskjöld O Stål S Thorstenson PE Jönsson G Landberg 2005 Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer J Clin Oncol 23 4695 4704 10.1200/JCO.2005.08.126 16034044 (Pubitemid 46224072)
25. L Rydén M Stendahl H Jonsson S Emdin NO Bengtsson G Landberg 2005 Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response Breast Cancer Res Treat 89 135 143 10.1007/s10549-004-1655-7 15692755 (Pubitemid 40249047)
26. V Guarneri F Piacentini G Ficarra A Frassoldati R D'Amico S Giovannelli A Maiorana G Jovic P Conte 2009 A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy Ann Oncol 20 1193 1198 1:STN:280:DC%2BD1MvivFWqtQ%3D%3D 10.1093/annonc/mdn761 19221152
27. SR Johnston G Saccani-Jotti IE Smith J Salter J Newby M Coppen SR Ebbs M Dowsett 1995 Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer Cancer Res 55 3331 3338 1:CAS:528:DyaK2MXnt1ansb4%3D 7614468
28. JM Knowlden IR Hutcheson HE Jones T Madden JM Gee ME Harper D Barrow AE Wakeling RI Nicholson 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells Endocrinology 144 1032 1044 1:CAS:528: DC%2BD3sXhslCqtro%3D 10.1210/en.2002-220620 12586780 (Pubitemid 36262870)
29. G Bunone PA Briand RJ Miksicek D Picard 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation EMBO J 15 2174 2183 1:CAS:528:DyaK28XjtFyjtrs%3D 8641283
30. H Lee W Bai 2002 Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation Mol Cell Biol 22 5835 5845 1:CAS:528:DC%2BD38XlslyjtLg%3D 10.1128/MCB.22.16.5835-5845.2002 12138194 (Pubitemid 34815832)
31. MC Gutierrez S Detre S Johnston SK Mohsin J Shou DC Allred R Schiff CK Osborne M Dowsett 2005 Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase J Clin Oncol 23 2469 2476 1:CAS:528:DC%2BD2MXjvVyktL8%3D 10.1200/JCO.2005.01.172 15753463 (Pubitemid 47050837)
32. S Svensson K Jirström L Rydén G Roos S Emdin MC Ostrowski G Landberg 2005 ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis Oncogene 24 4370 4379 1:CAS:528:DC%2BD2MXlsVWmt74%3D 10.1038/sj.onc.1208626 15806151 (Pubitemid 40961760)
33. J Bergqvist G Elmberger J Odh B Linderholm J Bjohle H Hellborg H Nordgren AL Borg L Skoog J Bergh 2006 Activated ERK1/2 and phosphorylated oestrogen receptor alpha are associated with improved breast cancer survival in women treated with tamoxifen Eur J Cancer 42 1104 1112 1:CAS:528:DC%2BD28Xks1ertbg%3D 10.1016/j.ejca.2006.01.028 16603346
34. X Qi NM Pohl M Loesch S Hou R Li JZ Qin A Cuenda G Chen 2007 p38alpha antagonizes p38gamma activity through c-Jun-dependent ubiquitin-proteasome pathways in regulating Ras transformation and stress response J Biol Chem 282 31398 31408 1:CAS:528:DC%2BD2sXhtFykurjF 10.1074/jbc.M703857200 17724032 (Pubitemid 350044894)